Express News | Matinas BioPharma Holdings Inc : Alliance Global Partners Initiates Coverage With Buy Rating and $0.6 Target Price
ReutersApr 26 08:51 ET
Matinas BioPharma's Multi-Million Share Sale and Lock-Up Deal
TipRanksApr 5 07:12 ET
Express News | Matinas BioPharma Prices $10M Registered Direct Offering At A Combined Offering Price Of $0.30 Per Share And Accompanying Warrant
Moomoo 24/7Apr 3 08:34 ET
Matinas BioPharma Prices $10 Million Registered Direct Offering
BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company focused on delivering groundbreaking
GlobeNewswireApr 3 08:30 ET
Matinas BioPharma (MTNB) Gets a Buy From Maxim Group
TipRanksApr 2 10:35 ET
12 Health Care Stocks Moving In Monday's After-Market Session
GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in
BenzingaApr 1 16:31 ET
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript
Yahoo FinanceApr 1 14:24 ET
Earnings Call Summary | Matinas BioPharma(MTNB.US) Q4 2023 Earnings Conference
The following is a summary of the Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript:Financial Performance:Matinas BioPharma reported a revenue of $1.1 million for 2023, primaril
moomoo AIMar 29 00:05 ET · Conference Call
Matinas BioPharma Updates Presentation for Investor Outreach
TipRanksMar 28 09:13 ET
Q4 2023 Matinas BioPharma Holdings Inc Earnings Call
Yahoo FinanceMar 28 06:46 ET
Express News | Matinas BioPharma Hldgs Q4 EPS $(0.03) Down From $(0.02) YoY
Moomoo 24/7Mar 27 23:42 ET
Matinas Biopharma GAAP EPS of -$0.11, Revenue of $1.1M
Seeking AlphaMar 27 16:46 ET
Matinas BioPharma FY23 EPS $(0.11) Vs $(0.10) YoY
2023 Financial ResultsRevenue for 2023 was $1.1 million, which was generated from the Company's research collaborations with BioNTech SE and Genentech Inc. This compares with revenue for 2022 of $3.2
BenzingaMar 27 16:34 ET
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) reports 2023 financial results and provides a business update.
Matinas BioPharmaMar 27 16:05 ET
Matinas BioPharma's LNC Technology Promises Safer Chemotherapy
TipRanksMar 25 08:22 ET
Express News | Matinas BioPharma Announces Results From An Additional In Vivo Study In Healthy Mice With An Oral LNC Formulation Of Docetaxel, A Chemotherapeutic Agent Used In The Management Of Multiple Metastatic And Unresectable Tumors
Moomoo 24/7Mar 25 08:16 ET
Matinas BioPharma Announces Positive in Vivo Safety Data With Its Oral LNC-Docetaxel Formulation
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel Results build on data
GlobeNewswireMar 25 08:00 ET
Matinas BioPharma's MAT2203 Shows Promising Clinical Results
TipRanksMar 22 09:33 ET
Express News | Matinas BioPharma Announces Complete Clinical Response In Three Patients With Serious Invasive Fusarium Infection Following Treatment With MAT2203
Moomoo 24/7Mar 22 09:16 ET
Three Patients With Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces complete clinical response in three patients with serious invasive fusarium infection following treatment with MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B.
GlobeNewswireMar 22 09:15 ET
No Data
No Data